Carter Angela M, Cymbalista Charlotte M, Spector Tim D, Grant Peter J
Academic Unit of Molecular Vascular Medicine, The LIGHT Laboratories, University of Leeds. Leeds LS2 9JT, UK.
Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2783-9. doi: 10.1161/ATVBAHA.107.153221. Epub 2007 Oct 11.
The relative balance between clot formation and fibrinolysis is considered to reflect thrombotic potential following vascular injury. The aims of the present study were to (1) to determine the contribution of genetic and environmental factors to variance in measures of clot structure/function in the Leeds Family Study, and (2) to determine the relationship between measures of clot structure/function and cardiovascular risk.
Using high throughput turbidimetric assays, heritabilities of measures of clot formation, clot structure, and clot lysis were approximately 0.30. Fibrinogen contributed to variance in all measures and plasminogen activator inhibitor-1 to variance in lysis variables. Subjects at increased cardiovascular risk due to the presence of the metabolic syndrome (MetS) had increased clot density (MaxAbs(C): 0.358 [0.340, 0.375]au) and prolonged lysis times (Lys(T): 510 [6569, 7939]s) compared with those without MetS (MaxAbs(C): 0.319 [0.310, 0.328]au, P=0.003; Lys(T): 7221 [4884, 5328]s, P<0.001). Furthermore, measures of clot structure/function increased progressively with increasing number of MetS components.
This study indicates that genetic factors contribute modestly to variance in clot structure/function and that clot structure/function is related to presence of the MetS and number of MetS components. Identification of the genetic and environmental factors influencing clot structure/function may further our understanding of the underlying factors predisposing to cardiovascular disease.
凝血与纤溶之间的相对平衡被认为反映了血管损伤后的血栓形成潜能。本研究的目的是:(1)在利兹家族研究中确定遗传和环境因素对凝血结构/功能测量指标变异的贡献;(2)确定凝血结构/功能测量指标与心血管风险之间的关系。
使用高通量比浊法,凝血形成、凝血结构和凝血溶解测量指标的遗传度约为0.30。纤维蛋白原对所有测量指标的变异有贡献,纤溶酶原激活物抑制剂-1对溶解变量的变异有贡献。与无代谢综合征(MetS)的受试者相比,因存在MetS而心血管风险增加的受试者凝血密度增加(最大吸光度(C):0.358[0.340,0.375]au),溶解时间延长(溶解时间(T):510[6569,7939]秒)(最大吸光度(C):0.319[0.310,0.328]au,P = 0.003;溶解时间(T):7221[4884,5328]秒,P < 0.001)。此外,凝血结构/功能测量指标随着MetS组分数量的增加而逐渐增加。
本研究表明遗传因素对凝血结构/功能变异的贡献较小,且凝血结构/功能与MetS的存在及MetS组分数量有关。识别影响凝血结构/功能的遗传和环境因素可能会加深我们对心血管疾病潜在易患因素的理解。